Previous Article | Next Article ![]()
Molecular and Cellular Biology, August 2006, p. 6272-6282, Vol. 26, No. 16
0270-7306/06/$08.00+0 doi:10.1128/MCB.00472-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Department of Developmental Neurobiology,1 Animal Resource Center, St. Jude Children's Research Hospital, Memphis, Tennessee 381052
Received 17 March 2006/ Returned for modification 15 April 2006/ Accepted 1 June 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
CrkL-knockout mice exhibit defects in multiple cranial and cardiac neural crest derivatives, and they do not survive embryogenesis (6). Interestingly, the steady-state level of Crk protein was not altered by the absence of CrkL. This result, together with the embryonic lethality of CrkL-knockout mice, suggests that Crk does not compensate for CrkL functions in vivo. Imaizumi et al. (8) reported a gene-trap mutation in the mouse Crk gene in which truncated CrkI-like proteins lacking the C-terminal SH3 domain were expressed. This CrkII-specific gene disruption did not result in any obvious abnormalities, which suggests that the C-terminal SH3 domain of CrkII is not essential. However, it is still unclear whether CrkI can compensate for the loss of CrkII or whether the loss of both CrkI and CrkII can be compensated for by CrkL. Therefore, it is necessary to generate Crk-knockout mice lacking both CrkI and CrkII to address the in vivo functions of these variants. Here we show that CrkI and CrkII are essential for normal embryonic development and that their in vivo functions are distinct from those of CrkL.
| MATERIALS AND METHODS |
|---|
|
|
|---|
|
Preparation of MEFs. Mouse embryonic fibroblasts (MEFs) were prepared as follows. Embryos derived from intercrosses of Crk+/ mice were harvested at embryonic day 13.5 (E13.5). Heads and viscera were removed and used to extract genomic DNA for Southern hybridization analysis. The remaining embryonic tissue was minced and treated with trypsin-EDTA (Invitrogen), and dissociated cells were cultured in Dulbecco's modified Eagle's medium (Cambrex) supplemented with 10% fetal bovine serum (HyClone), L-glutamine, penicillin, and streptomycin at 37°C under 5% CO2.
Western blot analysis. Western blotting was carried out as described previously (11). Lysates of MEFs were prepared using 1% NP-40 lysis buffer containing 20 mM Tris-HCl adjusted to pH 7.5, 150 mM NaCl, 1 mM EDTA, 20 mM NaF, 0.5 mM Na3VO4, 10% glycerol, and the protease inhibitor cocktail Complete Mini (Roche). After quantifying the protein content of each cell lysate using the Bio-Rad protein assay kit, total cell lysates containing the same amount of protein were loaded, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to nitrocellulose membranes (Invitrogen). Membranes were then subjected to Western blot analysis using anti-Crk (BD Pharmingen), anti-CrkL (c-20; Santa Cruz), and anti-Shp2 (sc-7384; Santa Cruz) antibodies. Immunodetection was performed using the WestDura chemiluminescence kit (Pierce).
Morphological and histological analyses. Embryos at different stages were dissected from mouse uteri and carefully examined under a dissecting microscope to determine whether they were alive by detecting the heartbeat and the blood supply to the yolk sac. Only live embryos were processed. Embryos and placentas were fixed overnight in 4% paraformaldehyde at 4°C, rinsed with phosphate-buffered saline (PBS; Mediatech), and incubated in PBS at 4°C until use. Where indicated, pictures of whole mouse embryos were taken after fixation. Fixed embryos were embedded in paraffin and sectioned at a thickness of 5 µm. Every tenth section was stained with hematoxylin and eosin, and sections with similar anatomical planes were chosen to take images. Slides were photographed using an Axioplan Zeiss microscope (Zeiss) and an RT color SPOT camera (Diagnostic Instruments) to obtain pictures of whole mouse embryos.
Immunohistochemistry. Sections embedded in paraffin were processed for deparaffinization and rehydration followed by antigen retrieval in 10 mM sodium citrate at 80°C, as described previously (22). Slides were treated with 1% H2O2, blocked in PBS supplemented with 3.5% bovine serum albumin, and incubated with anti-smooth muscle actin (SMA) antibody (1A4; DakoCytomation) and anti-CD34 antibody (RAM34; PharMingen) overnight at room temperature. Immunoreactivity was detected using the Vectastain Elite ABC kit (Vector Laboratories) and the diaminobenzidine reagent set (Kirkegaard and Perry Laboratories) according to the manufacturers' instructions. Slides were dehydrated, mounted by standard techniques, and analyzed using an Olympus BX60 microscope. Images were acquired with a Hamamatsu (Bridgewater) C5810 video camera and imported directly into Adobe Photoshop 7.0 (Adobe Systems).
| RESULTS |
|---|
|
|
|---|
Breeding among Crk+/ mice was carried out, and MEFs and genomic DNA were prepared from the embryos. PCR (data not shown) and Southern hybridization analysis (Fig. 1B) of the genomic DNA showed that the wild-type Crk allele was absent in Crk/ MEFs, whereas Crk+/ MEFs contained both wild-type and Crk-null alleles. Western blot analysis of the MEF lysates clearly indicated that CrkI and CrkII proteins were not detected in Crk/ MEFs and that their expression was reduced in Crk+/ MEFs (Fig. 1C). On the other hand, there was no obvious change in the expression of a closely related protein, CrkL, or that of an SH2-containing tyrosine phosphatase, Shp-2. These results suggest that deletion of the first exon of the Crk gene leads to the complete loss of CrkI and CrkII proteins without affecting the CrkL expression.
Viability of Crk-null mice and embryos. Intercrosses among Crk+/ mice were performed, and all pups that died after birth or survived to weaning were genotyped. Of 164 pups examined, 64 (39.0%) were wild type, 97 (59.1%) were Crk+/, and only 3 (1.8%) were Crk/ (they died shortly after birth). These results suggest that most Crk/ mice (about 95%) die before birth and the few that are born die perinatally. Therefore, we examined embryos from intercrosses at different stages and used their yolk sacs to prepare genomic DNA for genotyping (Table 1) to determine the timing of embryonic lethality. Because very few Crk/ pups were born, we collected embryos from later stages of embryonic development. At E18.5, no Crk/ embryos examined were alive. At E17.5, 3 viable embryos out of 44 (6.8%) were Crk/, and at E15.5, 7 embryos out of 152 (4.6%) were Crk/. These results indicate that the survival rate of Crk/ embryos at E15.5 through E18.5 is far below the expected level of 25%. In contrast, at E13.5 and E11.5, the survival rates for Crk/ embryos approached 25%. We found 7 live Crk/ embryos and 1 dead Crk/ embryo at E13.5 and 7 live and 21 dead Crk/ embryos at E15.5. This finding suggested that the majority of Crk/ embryos die during the period from E13.5 to E15.5. However, the time of death was variable as a few embryos died later. (For example, we found four dead Crk/ embryos at E17.5.) This variation in the timing of lethality may be contributed to, at least in part, by the mixed strain background. When the strain background was shifted to an almost pure FVB background, most Crk/ embryos died at between E15.5 and E18.5 and they showed similar phenotypes.
|
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Most of the proteins that interact with the SH3 domains of Crk, including C3G, DOCK180, the Abl family, HPK1, KHS, and phosphatidylinositol 3-kinase, bind to the N-terminal SH3 domain (reviewed in reference 5). The function of the C-terminal SH3 domain of CrkII is still poorly understood. In overexpression studies, CrkII is significantly less active than CrkI at inducing tyrosine phosphorylation of p130Cas, morphological alterations, and cell transformation (13, 16). This finding suggests that the C-terminal SH3 domain plays a negative regulatory role.
Recently, the C-terminal SH3 domain and an adjacent linker region were shown to be necessary for transactivation of the Abl tyrosine kinase (20). In addition, the C-terminal SH3 domain of CrkII was found to be required for engulfment of apoptotic cells and cell spreading on extracellular matrix in C. elegans (1). Therefore, our study, together with these previous reports, suggests that CrkI plays essential roles in development, whereas the C-terminal SH3 domain of CrkII contributes regulatory functions under certain circumstances. Mice lacking C3G, a guanine nucleotide exchange factor that binds to Crk and CrkL, die before E7.5 (17), which is earlier than the major period of lethality of Crk- or CrkL-mutant mice. Therefore, we cannot rule out the possibility that Crk and CrkL have both redundant and nonredundant functions during development, and it is still unclear whether CrkII is sufficient to replace CrkI.
The edema and hemorrhagic edema observed on the snout of Crk/ embryos were similar to those observed in C3Ggt/gt mutant mice, which express a fusion protein encoding the first 19 amino acids of C3G followed by ß-galactosidase and neomycin phosphotransferase (27), although the reported hemorrhage near the hindbrain of C3Ggt/gt embryos was not observed in Crk/ embryos. Furthermore, both mutants exhibit similar defects in smooth muscle cells. These results are consistent with observations indicating that Crk and C3G are closely connected in many signaling pathways. Interestingly, in vascular smooth muscle cells, Crk and its substrate p130Cas function in angiotensin II signaling to mediate smooth muscle contraction (23, 24). Recently, Crk and p130Cas were shown to play similar roles in regulating actin dynamics and smooth muscle contraction (25, 26). In addition, mice lacking p130Cas exhibited dilated blood vessels (7). Therefore, the p130Cas-Crk-C3G pathway most likely contributes to the maintenance of vascular integrity by regulating smooth muscle contraction.
The placenta of Crk/ embryos developed normally (data not shown); thus, it is quite possible that the cardiovascular failure in Crk/ embryos such as the poorly developed heart and defects in blood vessels results in a significant compromise of the circulatory system and leads to embryonic lethality. However, given the broad role of Crk in a variety of biological processes, we cannot rule out the possibility that other, undetected defects contribute to the death of Crk-null embryos.
Cleft palate was observed occasionally in Crk/ embryos. Cleft palate is a multifactorial disease that often results from a combination of genetic and environmental factors (reviewed in reference 9). Mice deficient in growth factors and growth factor receptors such as transforming growth factor ß3 (10, 18), platelet-derived growth factor C (PDGF-C) (3), and epidermal growth factor receptor (EGFR) (15) also exhibit cleft palate. Because Crk functions in growth factor receptor signaling pathways, it may participate in palate formation by mediating the signals downstream of multiple growth factor receptors or non-receptor tyrosine kinases. The partial penetration of the defect in Crk/ mice indicates that other factors can compensate for the loss of Crk.
In contrast to the low frequency of the cleft palate phenotype, edema at the anterior end of the nasopharynx, where nasal septum and the primary palate fuse, was detected in all Crk/ embryos examined. We do not yet understand the biological significance of edema in the nasopharynx; the precipitating cause of edema on the face and in the nasopharynx is also unclear. One possible explanation is that a defect in the mucosa/submucosal layers leads to separation of the two layers and provides a space that can fill with extracellular fluids. Interestingly, cleft palate and hemorrhagic edema on the face have also been seen in PDGF-C-deficient mice (3). Most of the defects found in Crk/ embryos, including hemorrhagic edema, defective vascular smooth muscle cells, and edema in the nasopharynx, occurred primarily at the midline of the head. Since EGFR signaling is required for formation of head midline structures in Drosophila (4), Crk may specifically contribute to the formation of some midline structures by signaling downstream of EGFR.
Both Crk and CrkL have been reported to be ubiquitously expressed during development (2). Furthermore, Prosser et al. (19) reported mRNA and protein expression for all Crk proteins in all mouse tissues tested (including the heart). We confirmed the broad expression pattern of Crk and CrkL in early embryos, including the developing heart and the craniofacial region affected by the absence of Crk, in our recently published Gene Expression Atlas (GENSAT) project (http://www.stjudebgem.org/web/view/probe/viewProbeDetails.php?id=401 and http://www.stjudebgem.org/web/view/probe/viewProbeDetails.php?id=402) (12). We have been able to grow fibroblasts from E13.5 Crk/ embryos, and so far they exhibit normal growth properties. At present, it is hard to pinpoint exactly which cells cause the developmental abnormalities we report here and it is possible they are consequences of early developmental errors that could either be cell extrinsic or cell intrinsic. The best way to address these interesting possibilities and to investigate the complex biological functions of both Crk and CrkL will be to use conditional alleles.
| ACKNOWLEDGMENTS |
|---|
This work was supported in part by grant 5R37NS036558 from NINDS, Cancer Center Support CA21765 from NCI, and the American Lebanese Syrian Associated Charities.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. de Jong, R., L. Haataja, J. W. Voncken, N. Heisterkamp, and J. Groffen. 1995. Tyrosine phosphorylation of murine Crkl. Oncogene 11:1469-1474.[Medline]
3. Ding, H., X. Wu, H. Bostrom, I. Kim, N. Wong, B. Tsoi, M. O'Rourke, G. Y. Koh, P. Soriano, C. Betsholtz, T. C. Hart, M. L. Marazita, L. L. Field, P. P. Tam, and A. Nagy. 2004. A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. Nat. Genet. 36:1111-1116.[CrossRef][Medline]
4. Dumstrei, K., C. Nassif, G. Abboud, A. Aryai, A. Aryai, and V. Hartenstein. 1998. EGFR signaling is required for the differentiation and maintenance of neural progenitors along the dorsal midline of the Drosophila embryonic head. Development 125:3417-3426.[Abstract]
5. Feller, S. M. 2001. Crk family adaptorssignalling complex formation and biological roles. Oncogene 20:6348-6371.[CrossRef][Medline]
6. Guris, D. L., J. Fantes, D. Tara, B. J. Druker, and A. Imamoto. 2001. Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nat. Genet. 27:293-298.[CrossRef][Medline]
7. Honda, H., H. Oda, T. Nakamoto, Z. Honda, R. Sakai, T. Suzuki, T. Saito, K. Nakamura, K. Nakao, T. Ishikawa, M. Katsuki, Y. Yazaki, and H. Hirai. 1998. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat. Genet. 19:361-365.[CrossRef][Medline]
8. Imaizumi, T., K. Araki, K. Miura, M. Araki, M. Suzuki, H. Terasaki, and K. Yamamura. 1999. Mutant mice lacking Crk-II caused by the gene trap insertional mutagenesis: Crk-II is not essential for embryonic development. Biochem. Biophys. Res. Commun. 266:569-574.[CrossRef][Medline]
9. Jugessur, A., and J. C. Murray. 2005. Orofacial clefting: recent insights into a complex trait. Curr. Opin. Genet. Dev. 15:270-278.[CrossRef][Medline]
10. Kaartinen, V., J. W. Voncken, C. Shuler, D. Warburton, D. Bu, N. Heisterkamp, and J. Groffen. 1995. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat. Genet. 11:415-421.[CrossRef][Medline]
11. Keshvara, L., S. Magdaleno, D. Benhayon, and T. Curran. 2002. Cyclin-dependent kinase 5 phosphorylates disabled 1 independently of Reelin signaling. J. Neurosci. 22:4869-4877.
12. Magdaleno, S., P. Jensen, C. L. Brumwell, A. Seal, K. Lehman, A. Asbury, T. Cheung, T. Cornelius, D. M. Batten, C. Eden, S. M. Norland, D. S. Rice, N. Dosooye, S. Shakya, P. Mehta, and T. Curran. 2006. BGEM: an in situ hybridization database of gene expression in the embryonic and adult mouse nervous system. PLoS Biol. 4:e86. [Online.] doi:10.1371/journal.pbio.0040086.[CrossRef][Medline]
13. Matsuda, M., S. Tanaka, S. Nagata, A. Kojima, T. Kurata, and M. Shibuya. 1992. Two species of human CRK cDNA encode proteins with distinct biological activities. Mol. Cell. Biol. 12:3482-3489.
14. Mayer, B. J., M. Hamaguchi, and H. Hanafusa. 1988. A novel viral oncogene with structural similarity to phospholipase C. Nature 332:272-275.[CrossRef][Medline]
15. Miettinen, P. J., J. R. Chin, L. Shum, H. C. Slavkin, C. F. Shuler, R. Derynck, and Z. Werb. 1999. Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure. Nat. Genet. 22:69-73.[CrossRef][Medline]
16. Ogawa, S., H. Toyoshima, H. Kozutsumi, K. Hagiwara, R. Sakai, T. Tanaka, N. Hirano, H. Mano, Y. Yazaki, and H. Hirai. 1994. The C-terminal SH3 domain of the mouse c-Crk protein negatively regulates tyrosine-phosphorylation of Crk associated p130 in rat 3Y1 cells. Oncogene 9:1669-1678.[Medline]
17. Ohba, Y., K. Ikuta, A. Ogura, J. Matsuda, N. Mochizuki, K. Nagashima, K. Kurokawa, B. J. Mayer, K. Maki, J. Miyazaki, and M. Matsuda. 2001. Requirement for C3G-dependent Rap1 activation for cell adhesion and embryogenesis. EMBO J. 20:3333-3341.[CrossRef][Medline]
18. Proetzel, G., S. A. Pawlowski, M. V. Wiles, M. Yin, G. P. Boivin, P. N. Howles, J. Ding, M. W. Ferguson, and T. Doetschman. 1995. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat. Genet. 11:409-414.[CrossRef][Medline]
19. Prosser, S., E. Sorokina, P. Pratt, and A. Sorokin. 2003. CrkIII: a novel and biologically distinct member of the Crk family of adaptor proteins. Oncogene 22:4799-4806.[CrossRef][Medline]
20. Reichman, C., K. Singh, Y. Liu, S. Singh, H. Li, J. E. Fajardo, A. Fiser, and R. B. Birge. 2005. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain. Oncogene 24:8187-8199.[Medline]
21. Reichman, C. T., B. J. Mayer, S. Keshav, and H. Hanafusa. 1992. The product of the cellular crk gene consists primarily of SH2 and SH3 regions. Cell Growth Differ. 3:451-460.[Abstract]
22. Romer, J. T., H. Kimura, S. Magdaleno, K. Sasai, C. Fuller, H. Baines, M. Connelly, C. F. Stewart, S. Gould, L. L. Rubin, and T. Curran. 2004. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/)p53(/) mice. Cancer Cell 6:229-240.[CrossRef][Medline]
23. Sayeski, P. P., M. S. Ali, J. B. Harp, M. B. Marrero, and K. E. Bernstein. 1998. Phosphorylation of p130Cas by angiotensin II is dependent on c-Src, intracellular Ca2+, and protein kinase C. Circ. Res. 82:1279-1288.
24. Takahashi, T., Y. Kawahara, T. Taniguchi, and M. Yokoyama. 1998. Tyrosine phosphorylation and association of p130Cas and c-Crk II by ANG II in vascular smooth muscle cells. Am. J. Physiol. 274:H1059-H1065.[Medline]
25. Tang, D. D., and J. Tan. 2003. Role of Crk-associated substrate in the regulation of vascular smooth muscle contraction. Hypertension 42:858-863.
26. Tang, D. D., W. Zhang, and S. J. Gunst. 2005. The adapter protein CrkII regulates neuronal Wiskott-Aldrich syndrome protein, actin polymerization, and tension development during contractile stimulation of smooth muscle. J. Biol. Chem. 280:23380-23389.
27. Voss, A. K., P. Gruss, and T. Thomas. 2003. The guanine nucleotide exchange factor C3G is necessary for the formation of focal adhesions and vascular maturation. Development 130:355-367.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|